AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04742790 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Body Sway Test
Description: Body sway will be assessed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment, using a body sway meter and with eyes closed. The body sway meter allows measurement of body movements in a single plane, providing a measure of postural stability. The method has been used to demonstrate effects of sleep deprivation, ethanol and psychoactive drugs. All body movements over a 2-min period are integrated and expressed as millimeters of sway.
Study NCT04742790 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: N-back working memory test
Description: Working memory performance will be assessed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. In this test, a series of letters are shown to the participant on a computer screen. The test includes three conditions with increased working memory load. The 0-back condition simply requires to indicate whether the presented letter is the letter X or another letter. In the 1-back condition, participants are requested to indicate whether the displayed letter is identical to the preceding letter. In the 2-back condition, participants are required indicate whether the letter is repeated with one other letter in between (e.g., B ... C ... B).
Study NCT04742790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Description: Before (visit 1) and 7-10 after (visit 2) initiating the combination treatment, but also daily between the two visits, 14 days, 1 month, 3 months and 6 months after treatment initiation, patient-reported outcomes will be collected to assess clinical effects and side-effects of the combination treatmen These include the short form of the Brief Pain Inventory (BPI), the PROMIS PQ-NEURO score for neuropathic pain, the Stanford Sleepiness Scale (SSS), and the PROMIS Neuro-QOL self-assessment of cognitive functioning.
Study NCT05752734 — intervention group
Intervention type: DRUG
Intervention: Group D
Description: Patients who received 8 mg dexamethasone before bariatric surgery will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation.
Study NCT05752734 — intervention group
Intervention type: DRUG
Intervention: Group C
Description: Patients not administered dexamethasone will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation.
Study NCT05424432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Toripalimab
Description: Toripalimab 240mg every 3 weeks for two cycles (D2,D23)
Study NCT05424432 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short Course Neoadjuvant Radiotherapy
Description: 30 Gy in 12 fractions, 1 fraction per day, 5 days per week, D3-D18
Study NCT05075798 — intervention group
Intervention type: OTHER
Intervention: No intervention,
Description: pure observational study
Study NCT05816603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real Soterix Mini-CT tDCS stimulator
Description: Real transcranial electrical stimulation at 2mA intensity will be delivered to the left dorsolateral prefrontal cortex, 20 minutes/day, 14-day duration.
Study NCT05816603 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Soterix Mini-CT tDCS stimulator
Description: Sham stimulation to the left dorsolateral prefrontal cortex, 20 minutes/day, 14-day duration. The device will ramp up and ramp down current delivery from 0 mA -2 mA - 0 mA over 30 seconds at the start of the 20-minute protocol with no active stimulation until the end of the 20 minutes, at which time the 30-second ramp up/ramp down will be repeated.
Study NCT06290284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long Peripheral Catheter
Description: PowerGlide Pro™ Midline Catheter
Study NCT06290284 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Intra-Venous Catheter
Description: Venflon™ Pro Safety Needle Protected IntraVenous Cannula
Study NCT05335863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement
Description: Participants must consume 416 mL of ONS FontActiv® DiaBest HP / HC vanilla flavor. A maximum time of 10 min will be given to consume the entire product.
Study NCT05335863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: Participants must consume a 50 g glucose solution in 10 min to obtain the ares under the curve (AUC) data from glucose consumption
Study NCT05410301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Static Magnetic and Electric (sBE) device
Description: Home-based Static Magnetic and Electric (sBE) device that is slept in
Study NCT05410301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Chemotherapy drug
Study NCT05410301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Chemotherapy and targeted therapy drug
Study NCT06372457 — intervention group
Intervention type: DRUG
Intervention: Approved Hypertrophic Cardiomyopathy drug treatments
Description: As per product label
Study NCT06372457 — intervention group
Intervention type: DRUG
Intervention: Mavacamten
Description: As per product label
Study NCT05274126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient group/Passvers
Description: Passvers intervention aims at :~* helping patients followed in the centers, presenting a Severe and Persistent Mental Disorder (schizophrenia, mood disorder, autism spectrum disorder, etc.), at risk or in a situation of psychological disability, to enroll in a rehabilitation program towards recovery.~* supporting the emergence and construction of projects by the people themselves, and to accompany them to realize them.~* Encouraging the use of resources in their environment and common law mechanisms (city hall, department, associations, etc.) for better social integration.~* encouraging involvement in care understood as useful tools for the realization of the personal project.~Passvers also aims at :~* promoting a change in professional practices within the team, in favor of recovery-oriented practices based on the concept of engagement or empowerment.~* allowing cooperation between health and social structures aiming at destigmatizing mental illness.
Study NCT05662592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Broadband Light
Description: Broadband Light device will be used for treatment of pigmented skin lesions
Study NCT04551261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS4
Description: It is a new dihydropyrimidine antiviral drug that interferes the assembly of HBV core granule.
Study NCT04551261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: 1. It is HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection;~2. It is a CYP3A inhibitor combined with other drug to increase the exposure in human.
Study NCT04551261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: It is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.
Study NCT05538481 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interview
Description: A collection of individual cultural values and palliative care preferences within the focus group meetings
Study NCT05538481 — intervention group
Intervention type: OTHER
Intervention: Developed survey completion
Description: A collection of individual responses to a survey created after focus group completion and analysis
Study NCT05538481 — intervention group
Intervention type: OTHER
Intervention: Systems of Belief Inventory (SBI-15R)
Description: A 15-item questionnaire designed to measure religious and spiritual beliefs and practices and the social support derived from a community sharing those beliefs.
Study NCT05718648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550
Study NCT06278077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurexan
Description: The active ingredients are Passiflora incarnata Dil. D2 (0.6 mg / tablet), Avena sativa Dil. D2 (0.6 mg / tablet), Coffea arabica Dil. D12 (0.6 mg/tablet) and Zincum isovalerianicum Dil. D4 (0.6 mg / tablet). Inactive excipients are lactose monohydrate and magnesium stearate.
Study NCT06278077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains lactose monohydrate, magnesium stearate and looks identical to Neurexan in terms of taste, size, color and labelling.
Study NCT05959980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior cervical fixation surgery
Description: These patients will undergo posterior cervical fixation in the form of cervical lateral mass screw fixation in extension without decompression under general anesthesia.
Study NCT04875247 — intervention group
Intervention type: DEVICE
Intervention: IOLMaster 700 with central topography
Description: The time needed to perform the measurement using the IOLMaster700 equipment with central topography will be recorded.
Study NCT04875247 — intervention group
Intervention type: DEVICE
Intervention: IOLMaster 700 without central topography plus Cassini
Description: The time needed to perform the measurement using the IOLMaster700 equipment without central topography plus the Cassini equipment will be recorded.
Study NCT04875247 — intervention group
Intervention type: DEVICE
Intervention: IOLMaster 700 without central topography plus Pentacam
Description: The time needed to perform the measurement using the IOLMaster700 equipment without central topography plus the Pentacam equipment will be recorded.
Study NCT05179941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion with Indocyanine green
Description: Infusion of Indocyanine green to determine perfusion of the subscapularis tendon change after tenotomy vs peel technique and subsequent intra-operative repair.
Study NCT06275672 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted version of the mhGAP-IG
Description: An Ugandan adapted version of the mhGAP-IG CAMH module for identification, assessment, and management of common mental disorders in children and adolescents. The mhGAP-IG CAMH module further details six different protocols for the management of these mental health problems, primarily based on psychosocial and systemic interventions. The described psychosocial interventions can also be provided as general prevention for children with subclinical problems. Lastly, the module guides further follow-up assessment. Experts identified by the Ministry of Health will train trainers who train and follow-up teachers and health personnel receiving the intervention.
Study NCT05963321 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TDCS
Description: Two tDCS devices will be used simultaneously. The intervention consists of a tDCS session in which the active electrode will be located in the cerebellum and/or in the primary motor cortex (4 stimulation protocols that will be implemented; active cerebellum electrode and active M1 electrode, sham cerebellum electrode and active M1 electrode, active cerebellum and sham M1 electrode, sham cerebellar electrode and sham M1 electrode) and the cathode in the contralateral supraorbital region.
Study NCT05963321 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TDCS
Description: Two tDCS devices will be used simultaneously. The intervention consists of a tDCS session in which the active electrode will be located in the cerebellum and/or in the primary motor cortex (4 stimulation protocols that will be implemented; active cerebellum electrode and active M1 electrode, sham cerebellum electrode and active M1 electrode, active cerebellum and sham M1 electrode, sham cerebellar electrode and sham M1 electrode) and the cathode in the contralateral supraorbital region.
Study NCT04430569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Alteplase single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
Study NCT04430569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
Study NCT06225609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ghost ileostomy
Description: Laparoscopic or robotic surgery with ghost ileostomy
Study NCT06225609 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No ileostomy
Description: Laparoscopic or robotic surgery with no ileostomy
Study NCT05902702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nebulized isotonic saline
Description: The intervention will constitute nebulized isotonic saline.
Study NCT05902702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal irrigation with isotonic saline
Description: The intervention will constitute isotonic saline administered as nasal drops.
Study NCT05681130 — intervention group
Intervention type: OTHER
Intervention: questionaire
Description: two questionaires for each group
Study NCT06013618 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naxitamab monotherapy
Description: Naxitamab is administered on days 1, 3, and 5
Study NCT06013618 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GM-CSF
Description: Each treatment cycle is 28 days and is started with five days (days -4 to 0) of GM-CSF administered at 250 mcg/m2/day in advance of the start of naxitamab infusion. GM-CSF is thereafter administered at 500 mcg/m2/day on days 1 to 5.
Study NCT06013618 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.
Study NCT06013618 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.
Study NCT06013618 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naxitamab in combination therapy
Description: Naxitamab 2.25mg/kg IV will be administered on Days 2, 4, 8 and 10.
Study NCT06013618 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GM-CSF with combination regimen
Description: GM-CSF 250 mcg/m2/day will be administered subcutaneously on Days 6-10.
Study NCT05897814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Location of the epidural analgesia catheter
Description: Research of the location of the epidural analgesia catheter using M-mode and color Doppler (cD) ultrasonography.
Study NCT06318884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCTB35 injection
Description: SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and another appropriate dose of SCTB35 will be applied for the dose-expansion cohorts.
Study NCT04326530 — intervention group
Intervention type: DEVICE
Intervention: Pneumopipe® (European patent 12425057.2, Rome, Italy)
Description: Collection of VOCs on a cartridge after that the child has normally breathed in it for 3 min, both at the baseline and at the last visit.
Study NCT04326530 — intervention group
Intervention type: OTHER
Intervention: Other assessments
Description: * Spirometry, both at the baseline and at the last visit.~* 24-hour urine collection, both at the baseline and at the last visit.
Study NCT06013618 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sintilimab
Description: Sintilimab was administerd with 3mg/kg (max 200mg) on day 11 every 3 weeks.
Study NCT05733455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg)
Description: Participants will ingest two overencapsulated tablets of alpelisib at 23:00, along with a saltine cracker.
Study NCT05733455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (microcrystalline cellulose), 2 capsules
Description: Participants will ingest two capsules filled with microcrystalline cellulose at 23:00, along with a saltine cracker.
Study NCT05733455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Pro
Description: Continuous glucose monitoring for 24 hours (double blinded)
Study NCT05733455 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: FreeStyle Libre Pro
Description: Continuous glucose monitoring for 24 hours (double blinded)
Study NCT05733455 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT) with Trutol glucose beverage
Description: Participants will drink Trutol glucose beverage (D-glucose 75 g in 10 fl oz) and blood will be sampled at baseline and at 15, 30, 60, 90, 120, 150, and 180 minutes.
Study NCT05733455 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Oral glucose tolerance test (OGTT) with Trutol glucose beverage
Description: Participants will drink Trutol glucose beverage (D-glucose 75 g in 10 fl oz) and blood will be sampled at baseline and at 15, 30, 60, 90, 120, 150, and 180 minutes.
Study NCT06528561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sef-care program with exercise
Description: Self-care program with physical exercise with aerobic and muscular strength components implemented progressively according to the participant's clinical evolution
Study NCT06293872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12*2 mm length miniscrew
Description: Prior to mini-inplant insertion the patient will instructed to rinse mouth with chlorhexidine mouthwash, then local anesthesia will be applied.~The clinical implication for miniscrew insertion in the IZ crest of adults is 14 to 16 mm above the maxillary occlusal plane and the maxillary first molar.~The self-drilling screw is directed at 90° to the occlusal plane at this point. After the initial notch in the bone is created after couple of turns to the driver, the bone screw driver direction is changed by 55°-70° toward the tooth, downward, which aid in bypassing the roots of the teeth and directing the screw to the infra-zygomatic area of the maxilla. The bone screw is screwed until only the head of the screw is visible outside the alveolar mucosa.~Follow-up: C.B.C.T will be performed after surgery to verify the implant position relative to the adjacent roots
Study NCT06293872 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 12*2 mm length miniscrew
Description: Prior to mini-inplant insertion the patient will instructed to rinse mouth with chlorhexidine mouthwash, then local anesthesia will be applied.~The clinical implication for miniscrew insertion in the IZ crest of adults is 14 to 16 mm above the maxillary occlusal plane and the maxillary first molar.~The self-drilling screw is directed at 90° to the occlusal plane at this point. After the initial notch in the bone is created after couple of turns to the driver, the bone screw driver direction is changed by 55°-70° toward the tooth, downward, which aid in bypassing the roots of the teeth and directing the screw to the infra-zygomatic area of the maxilla. The bone screw is screwed until only the head of the screw is visible outside the alveolar mucosa.~Follow-up: C.B.C.T will be performed after surgery to verify the implant position relative to the adjacent roots
Study NCT06528561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sef-care program with exercise
Description: Self-care program with physical exercise with aerobic and muscular strength components implemented progressively according to the participant's clinical evolution
Study NCT06029686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stanford Glove
Description: The vibrotactile device sends weak non-painful pattern type vibratory stimulus to the fingertips and is non-invasive. Some patient may experience dyskinesia which can me medicated with a decrease in Parkinson's medication
Study NCT05733455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BOOST Plus nutritional beverage
Description: Participants will consume a quantity of BOOST Plus calculated to match their daily caloric needs, divided over three liquid meals.
Study NCT05733455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: BOOST Plus nutritional beverage
Description: Participants will consume a quantity of BOOST Plus calculated to match their daily caloric needs, divided over three liquid meals.
Study NCT05502497 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observational
Description: No application will be made to the control group.
Study NCT05502497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM Technique Application
Description: Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.